Literature DB >> 1698097

Effects of sodium butyrate and 5-azacytidine on DNA methylation in human tumor cell lines: variable response to drug treatment and withdrawal.

D E Cosgrove1, G S Cox.   

Abstract

The effect of butyrate (Btr) and 5-azacytidine (azaC) on genomic DNA methylation was examined in a variety of human tumor cell lines. Butyrate treatment differentially affected 5-methylcytosine (m5C) content in a cell type-specific manner. For example, incubation of CBT cells (glioblastoma multiforme) for 48 h in medium containing 2 mM Btr resulted in the hypomethylation of their DNA; after removal of the drug, the m5C content was rapidly (24 h) restored to its original level. In contrast, when HeLa cells (cervical carcinoma) were cultured for 48 h in 3 mM Btr, their genomic DNA became more extensively methylated relative to the untreated control, and the hypermethylated state was maintained for long periods in culture. Treatment of HeLa cell lines with azaC resulted in extensive demethylation of their DNA. Following removal of the drug, the DNA was rapidly remethylated to levels equal to or greater than those of the untreated cells. The hypermethylated state has remained stable for over 180 generations. Together, the data suggest that cells respond rapidly to alter drug-induced reductions in the m5C content of their DNA, and this response can subsequently result in overmethylation. In contrast, when drug-induced hypermethylation of genomic DNA occurs, it may persist for many cell generations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698097     DOI: 10.1016/0167-4781(90)90124-k

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent.

Authors:  V V Ogryzko; T H Hirai; V R Russanova; D A Barbie; B H Howard
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

2.  5-Azacytidine increases tanshinone production in Salvia miltiorrhiza hairy roots through epigenetic modulation.

Authors:  Bo-Cheng Yang; Meng-Shiou Lee; Ming-Kuem Lin; Wen-Te Chang
Journal:  Sci Rep       Date:  2022-06-07       Impact factor: 4.996

3.  Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate.

Authors:  Sabita N Saldanha; Rishabh Kala; Trygve O Tollefsbol
Journal:  Exp Cell Res       Date:  2014-02-08       Impact factor: 3.905

4.  Chromatin composition alterations and the critical role of MeCP2 for epigenetic silencing of progesterone receptor-B gene in endometrial cancers.

Authors:  Yongli Chu; Yanlin Wang; Guanghua Zhang; Haibin Chen; Sean C Dowdy; Yuning Xiong; Fengming Liu; Run Zhang; Jinping Li; Shi-Wen Jiang
Journal:  Cell Mol Life Sci       Date:  2014-02-15       Impact factor: 9.261

5.  The ER repeat protein YT521-B localizes to a novel subnuclear compartment.

Authors:  O Nayler; A M Hartmann; S Stamm
Journal:  J Cell Biol       Date:  2000-09-04       Impact factor: 10.539

6.  Antidepressant-like effect of sodium butyrate is associated with an increase in TET1 and in 5-hydroxymethylation levels in the Bdnf gene.

Authors:  Yabin Wei; Philippe A Melas; Gregers Wegener; Aleksander A Mathé; Catharina Lavebratt
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

7.  Use of 5-azacytidine in a proof-of-concept study to evaluate the impact of pre-natal and post-natal exposures, as well as within generation persistent DNA methylation changes in Daphnia.

Authors:  Camila Gonçalves Athanasio; Ulf Sommer; Mark R Viant; James Kevin Chipman; Leda Mirbahai
Journal:  Ecotoxicology       Date:  2018-04-05       Impact factor: 2.823

8.  The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.

Authors:  V El-Khoury; G Breuzard; N Fourré; J Dufer
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.